Taurine
As of the edition of 20 October 2026, Taurine is a small molecule: marketed, first approved in 1986 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Primene
- First approved
- 20 January 1986 (FR)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- Taisho Pharmaceutical; 2 holders in all
- Registered trials
- 18, 1 stopped early
- Disease areas
- Nutrition and metabolism; Cancer; Mental health; Nervous system; Digestive system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 0 | 2 | 0 |
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 6 | 1 | 4 | 0 |
| Phase 3 | 3 | 2 | 1 | 0 |
| Phase 4 | 2 | 1 | 1 | 0 |
| All trials | 18 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Applicant | 1997 to now |
| Taisho Pharmaceutical | Applicant | 2019 to now |